title: [Pneumology. Treatment of idiopathic pulmonary fibrosis: hopes and disappointment].
abstract: Idiopathic pulmonary fibrosis (IPF) is now recognized as a separate nosological entity. Despite the progresses in understanding the basic mechanisms of the disease, its prognosis remains poor. The classical treatment combines prednisone with a cytotoxic agent. Interferon gamma has the in vitro capacity of inhibiting fibroblasts proliferation. A pilot study showed positive results, but a more recent randomized double blind trial was unable to demonstrate a clear benefit to the patients. On the other hand there are many evidences for an oxydant-antioxydant imbalance in the pathogenesis of IPF. In a human controlled study N-acetylcysteine (NAC) at high doses (1800 mg per day orally) improved the pulmonary function tests when given on top of a combined therapy with prednisone and azathioprine.
authors.affiliation: Service de pneumologie, Hôpitaux universitaires de Genève, 1211 Genève 14. thierry.rochat@hcuge.ch
authors.forename: T
authors.initials: T
authors.lastname: Rochat
authors.forename: P
authors.initials: P
authors.lastname: Leuenberger
mesh_terms: D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D007371:Interferon-gamma